U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Imipenem-cilastatin-relebactam Injection
  1. Development Resources

Imipenem-cilastatin-relebactam Injection

FDA Identified Breakpoints

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacteriaceae a

≤1/4

2/4

≥4/4

≥25

21-24

≤20

Pseudomonas aeruginosa

≤2/4

4/4

≥8/4

≥23

20-22

≤19

Anaerobes b,c

≤4/4

8/4

≥16/4

-

-

-

S = Susceptible; I = Intermediate; R = Resistant

For disk diffusion, use paper disks impregnated with imipenem/relebactam at a concentration of 10/25 mcg/mL.

a Clinical efficacy was shown for Klebsiella aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Klebsiella oxytoca.
b Clinical efficacy was shown for Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides thetaiotaomicron, Fusobacterium nucleatum, Parabacteroides distasonis.
c Agar dilution method.